La cadena de opciones muestra datos clave de las opciones de acciones de Creative Medical Tech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Creative Medical Tech..

Creative Medical Tech (NASDAQ:CELZ) Bolsa, Cadena de Opciones

Creative Medical Tech

Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

Deep-pocketed investors have adopted a bearish approach towards Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CLS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Celestica. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 55% bearish. Among these notable options, 3 are puts, totaling $120,280, and 17 are calls, amounting to $746,958.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $175.0 for Celestica, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Celestica stands at 601.94, with a total volume reaching 980.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Celestica, situated within the strike price corridor from $85.0 to $175.0, throughout the last 30 days.
<h3>Celestica Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738694722_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$24.1</td>
<td>$21.7</td>
<td>$23.0</td>
<td>$105.00</td>
<td>$158.7K</td>
<td>2.7K</td>
<td align="right">102</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$45.5</td>
<td>$44.2</td>
<td>$45.01</td>
<td>$85.00</td>
<td>$54.0K</td>
<td>161</td>
<td align="right">58</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.7</td>
<td>$25.5</td>
<td>$25.7</td>
<td>$140.00</td>
<td>$51.4K</td>
<td>120</td>
<td align="right">22</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$40.9</td>
<td>$40.0</td>
<td>$40.39</td>
<td>$90.00</td>
<td>$48.4K</td>
<td>156</td>
<td align="right">56</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.8</td>
<td>$11.3</td>
<td>$11.35</td>
<td>$130.00</td>
<td>$45.4K</td>
<td>1.2K</td>
<td align="right">38</td>
</tr>
</tbody>
</table>

<h3>About Celestica</h3>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
After a thorough review of the options trading surrounding Celestica, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Celestica's Current Market Status</h3>
<ul>
<li>With a volume of 3,283,755, the price of CLS is up 8.55% at $131.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Celestica</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $125.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Securities persists with their Buy rating on Celestica, maintaining a target price of $107. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Celestica, maintaining a target price of $140. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Celestica with a target price of $115. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Celestica, maintaining a target price of $139. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Celestica, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Celestica's Options Frenzy: What You Need to Know

News

Spirit Aero Has Increased Fuselage Production From A Rate Of 21 A Month To 31 A Month, According To A Source Familiar With The Matter; Spirit Aero Spokesperson Joe Buccino Said The Company "Remains Committed To Meeting Our Customer's Production Targets."

BofA Securities analyst Wamsi Mohan reiterated a Buy rating on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/AAPL/analyst-ratings" rel="noreferrer noopener">price target of $265</a>.
As per SensorTower data, App Store revenues in the second quarter of fiscal 2025 (after 36 days) increased to $3.4 billion (+17%, according to data on developer revenue from SensorTower), with total downloads (iPhone + iPad) +6.5% (3.7 billion) during the same period. For January, App store revenue increased by +18% globally and +17% in China.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43468780/fox-q2-earnings-revenue-and-eps-beat-fall-sports-schedule-and-election-cycle-drove-performance-plans-new-streaming-service" rel="noreferrer noopener">Fox Q2 Earnings: Revenue And EPS Beat, Fall Sports Schedule and Election Cycle Drove Performance, Plans New Streaming Service</a>
In the second quarter of fiscal 2025 (after 36 days), Mohan noted an increase of app store dollars per download by +9.8%.
The rerating reflects stable cash flows, earnings resiliency and potential beneficiary of AI use on edge devices.
The Productivity category of Apps has been the fastest growing segment in the second quarter, with revenues rising +48% after 36 days. The growth in Productivity app revenue to Apple in the quarter has been driven by ChatGPT, which has seen daily active users grow from ~5.5 million in the first 36 days of the second quarter of fiscal 2024 to more than 15 million in the first 36 days of second-quarter of fiscal 2025.
So far, in the second quarter of fiscal 2025, App Store gaming revenue increased +12% to $1.7 billion, accounting for only 51% of total App Store revenue versus 53% a year ago. So far in the quarter, the second largest segment has been Entertainment (14%), Photo and video (7%), Social Networking (4%), Productivity (3%), and Other (21%).
Mohan noted strong diversification in app store revenue by category away from the Gaming segment as more developers from other categories monetize apps.
Apple noted that certain EU apps that do not conform to Apple&#8217;s standard of scrutiny over content are available to download. This ability to sideload apps is a result of the EU DMA restrictions, which might compromise user safety.
Mohan modeled services revenue growth of +12% for total services revenue in the second quarter of fiscal 2025 and +13% in fiscal 2025, which could be conservative if App Store strength persists.
Price Action: AAPL stock is up 1.64% at $231.75 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43468852/ferrari-q4-earnings-top-estimates-ceo-highlights-robust-growth-in-2025" target="_blank" rel="noreferrer noopener">Ferrari Q4 Earnings Top Estimates, CEO Highlights &#8216;Robust Growth&#8217; In 2025</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

AAPL

Apple's App Store Booms As ChatGPT, Productivity Apps Drive Revenue Growth, Analyst Says

Boeing's Mounir Says Co. Minimizing Supplier Work Transfers To Improve Quality; Supply Chain Exec Says Work Transfers Among Suppliers Are Leading Cause Of Quality Defects; Exec Says Spirit AeroSystems Quality Has Significantly Improved, Has Substantial Inventory Of 737 Fuselages Ready To Ship To Boeing Plant

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/goog/earnings">closing bell on Tuesday, Feb. 4.</a>
Analysts expect the California-based company to report quarterly earnings at $2.13 per share, up from $1.64 per share in the year-ago period. Alphabet projects quarterly revenue of $96.65 billion, compared to $ 86.31 billion a year earlier, according to data from Benzinga Pro.
Recent strength in advertising for Meta Platforms could foreshadow strong advertising strength for Alphabet, Bank of America analyst Justin Post recently said.
Alphabet shares fell 1.4% to close at $202.64 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GOOG/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Oppenheimer analyst Jason Helfstein maintained an Outperform rating and raised the price target from $215 to $225 on Jan. 30, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Scotiabank analyst Nat Schindler maintained a Sector Outperform rating and raised the price target from $212 to $240 on Jan. 24, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Jefferies analyst Brent Thill maintained a Buy rating and raised the price target from $220 to $235 on Oct. 30, 2024. This analyst has an accuracy rate of 77%.</li>
<li>Pivotal Research analyst Jeffrey Wlodarczak maintained a Buy rating and boosted the price target from $215 to $225 on Oct. 30, 2024. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating and increased the price target from $187 to $192 on Oct. 30, 2024. This analyst has an accuracy rate of 85%.</li>
</ul>
Considering buying GOOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-1024x580.png" alt="" class="wp-image-764391" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04043744/image-16.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Earnings

GOOG

GOOGL

Alphabet Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) reported upbeat second-quarter <a href="https://www.benzinga.com/quote/FN/earnings">results on Monday</a>.
Revenue was $833.6 million, beating the consensus of $814.3 million. Adjusted EPS of $2.61 exceeded the consensus of $2.50.
"Our telecom performance was very strong and benefited from both increasing demand for datacenter interconnect products as well as early progress from recent systems wins," Seamus Grady, Chief Executive Officer of Fabrinet, said. "While datacom demand has slightly moderated near-term we continue to anticipate more rapid growth as next-generation products ramp production. With several positive trends, we are very optimistic as we look to the third quarter and beyond."
Fabrinet expects third-quarter FY25 revenue of $850 million – $870 million, surpassing street view of $825.72 million. The company also projects adjusted EPS of $2.55 – $2.63 vs. street view of $2.55.
Fabrinet shares fell 9.6% to trade at $203.79 on Tuesday.
These analysts made changes to their price targets on Fabrinet following earnings announcement.
<ul>
<li>JP Morgan analyst Samik Chatterjee maintained Fabrinet with a Neutral and lowered the price target from $275 to $265.</li>
<li>Barclays analyst George Wang maintained Fabrinet with an Equal-Weight and lowered the price target from $292 to $245.</li>
<li>Rosenblatt analyst Mike Genovese maintained the stock with a Buy and raised the price target from $280 to $285.</li>
<li>Needham analyst Ryan Koontz, meanwhile, reiterated Fabrinet with a Buy and maintained a $280 price target.</li>
</ul>
Considering buying FN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-1024x483.png" alt="" class="wp-image-765483" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133927/image-29.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

These Analysts Revise Their Forecasts On Fabrinet After Q2 Results

TD Cowen analyst Jason Seidl maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Hold and raises the price target from $456 to $478.

SAIA

TD Cowen Maintains Hold on Saia, Raises Price Target to $478

Market volatility has intensified investors&#8217; focus on risk-adjusted strategies, with ETFs emerging as a key way to <a href="https://www.benzinga.com/etfs">gain exposure to high-growth stocks</a> without the &#8220;single-stock risk&#8221; string attached. 
Amid the back-to-back market developments, Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is making waves with <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">strong Q4 results</a> where it crushed analyst expectations.
For investors seeking exposure to Palantir without direct stock ownership, these are four ETFs to keep an eye on:
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43463909/palantir-stock-is-surging-tuesday-whats-going-on">Palantir Stock Is Surging Tuesday: What&#8217;s Going On?</a>
<ul>
<li>REX AI Equity Premium Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NASDAQ">AIPI</a>): In this ETF, Palantir holds the biggest piece of the pie, with 10.77% claim on the total assets. Expense ratio is 0.65%. The ETF inched up 0.4% on Feb. 4, 12.27 p.m. ET.</li>
</ul>
<ul>
<li>ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>): Palantir consistently ranks among ARKK's top 10 holdings, reflecting Cathie Wood's strong conviction in its AI and data-driven capabilities. As of today, Palantir accounts for approximately 5.43% of ARKK's portfolio. The expense ratio is 0.75%. The ETF is currently trading relatively flat.</li>
</ul>
<ul>
<li>Global X Funds Global X Defense Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>): The ETF, with an expense ratio of 0.5%, reserves about 10% of its assets for Palantir. The ETF has returned 35% in the past year. The ETF rose 2.27% as of writing on Feb. 4.</li>
</ul>
<ul>
<li>First Trust US Equity Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPX#NYSE">FPX</a>): Though this fund tracks newly public companies, Palantir has remained a top component despite trading on the market since 2020. Palantir, with its 1000+% growth since its IPO, is a success story on its own, and this ETF capitalizes on that. FPX has around 7.05% allocation to the company stock, appealing to investors targeting high-growth IPOs. The expense ratio is 0.59%. The ETF climbed 1.05% as of writing on Feb. 4.</li>
</ul>
These ETFs allow investors to benefit from Palantir's growth graph while spreading risk across multiple high-tech stocks.
<h3 class="wp-block-heading">Why Palantir Is A Stock To Watch</h3>
Palantir soared after issuing a 2025 revenue forecast of $3.75 billion, surpassing analysts' expectations of $3.54 billion. CEO Alex Karp attributed the bullish outlook to &#8220;untamed organic growth&#8221; in AI demand. The company also projected $1.56 billion in adjusted operating income, beating estimates of $1.37 billion.
In Q4 2024, revenue jumped 36% to $827.5 million, exceeding forecasts of $775.9 million, while profit (excluding certain items) hit 14 cents per share, topping estimates of 11 cents.
Fueled by AI momentum, Palantir's stock surged 340% in 2024. After markets opened Tuesday, shares spiked 27% to a record $106.76, marking their biggest intraday gain in a year, according to Bloomberg.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/25/02/43468406/treasury-etfs-in-focus-as-trumps-tariffs-feds-rate-decision-shake-bond-markets">Treasury ETFs In Focus As Trump&#8217;s Tariffs, Fed&#8217;s Rate Decision Shake Bond Markets</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Specialty ETFs

ETFs

AIPI

ARKK

PLTR

SHLD

Palantir Focused ETFs Spark Investor Interest: Here's Why

TD Cowen analyst John Kernan maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Buy and raises the price target from $258 to $268.

TD Cowen Maintains Buy on Ralph Lauren, Raises Price Target to $268

Editor&#8217;s Note: This article has been updated to correct inaccuracies in company location and financial comparisons.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/GOOG/earnings">closing bell on Tuesday, Feb. 4.</a>
Analysts expect the California-based company to report quarterly earnings at $2.13 per share, up from $1.64 per share in the year-ago period. Alphabet projects quarterly revenue of $96.65 billion, compared to $86.31 billion a year earlier, according to data from Benzinga Pro.
The company has beaten analyst estimates for revenue in seven straight quarters and topped analyst expectations for earnings per share in seven straight quarters.
With the recent buzz around Alphabet, some investors may be eyeing potential gains from the company's dividends too. At the moment, Alphabet offers an annual dividend yield of 0.39%, which is a quarterly dividend amount of 20 cents per share (80 cents a year).
To figure out how to earn $500 monthly from Alphabet, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Alphabet's $0.80 dividend: $6,000 / $0.80 = 7,500 shares.
So, an investor would need to own approximately $1,509,225 worth of Alphabet, or 7,500 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.80 = 1,500 shares, or $301,845 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
GOOG Price Action: Shares of Alphabet fell by 1.4% to close at $201.23 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

How To Earn $500 A Month From Alphabet Stock Ahead Of Q4 Earnings (CORRECTED)

TD Cowen analyst Lance Vitanza maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $55 to $51.

DKNG

TD Cowen Maintains Buy on DraftKings, Lowers Price Target to $51

TD Cowen analyst Lance Vitanza maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Buy and lowers the price target from $50 to $48.

TD Cowen Maintains Buy on Caesars Entertainment, Lowers Price Target to $48

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/CAH/earnings">results on Thursday</a>.
Cardinal Health posted adjusted earnings of $1.93 per share, beating market estimates of $1.76 per share. The company posted sales of $55.3 billion, topping expectations of $54.915 billion.
&#8220;We delivered strong second quarter financial results while taking significant strategic and operational actions to position us for future growth,&#8221; said Jason Hollar, CEO of Cardinal Health. &#8220;Led by robust demand across our Pharmaceutical and Specialty Solutions segment, we are again pleased to raise our fiscal 2025 enterprise guidance.&#8221;
Cardinal Health raised its FY25 non-GAAP earnings guidance from $7.75-$7.90 per share to $7.85-$8.00 per share.
Cardinal Health shares gained 1.3% to trade at $126.92 on Tuesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li>Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to $136.</li>
<li>JP Morgan analyst Lisa Gill maintained Cardinal Health with a Neutral and raised the price target from $142 to $145.</li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png" alt="" class="wp-image-765459" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04133226/image-2-5.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43463896/mcdonalds-to-290-here-are-10-top-analyst-forecasts-for-tuesday">McDonald&#8217;s To $290? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

TD Cowen analyst Lance Vitanza downgrades NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) from Buy to Hold and lowers the price target from $46 to $27.

Downgrades

NSSC

TD Cowen Downgrades NAPCO Security Techs to Hold, Lowers Price Target to $27

On Tuesday, Cumberland Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) released topline results from its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43459112/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-in-duch" rel="noreferrer noopener">Phase 2 FIGHT DMD trial</a>.
The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of <a target="_blank" href="https://www.benzinga.com/quote/CPIX" rel="noreferrer noopener">death in DMD patients</a>.
DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42419338/why-is-cumberland-pharmaceuticals-stock-trading-over-100-on-tuesday" rel="noreferrer noopener">Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?</a>
Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure.
The trial enrolled 41 patients who received either low-dose ifetroban (150 mg per day), high-dose ifetroban (300 mg per day), or placebo.
The study&#8217;s primary endpoint was an improvement in the heart&#8217;s left ventricular ejection fractions (LVEF), a key indicator of how well the heart is pumping blood.&nbsp;
Key findings include:
<ul>
<li>High-dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.</li>
<li>The high-dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%</li>
<li>The difference was even more pronounced when compared with propensity-matched natural history controls, with the high-dose treatment providing a significant 5.4% overall improvement in LVEF, while the control patients experienced a 3.6% decline.</li>
<li>Both doses of ifetroban were well-tolerated, with no serious drug-related events.</li>
</ul>
Ifetroban has received both&nbsp;Orphan Drug Designation&nbsp;and&nbsp;Rare Pediatric Disease Designation&nbsp;from the FDA. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.
Price Action: CPIX stock is up 23.01% at $2.62 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" target="_blank" rel="noreferrer noopener">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a></li>
</ul>

Biotech

Health Care

Movers

General

CPIX

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

HSBC analyst Edoardo Spina downgrades Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) from Buy to Hold and lowers the price target from $109 to $100.

HSBC Downgrades Autoliv to Hold, Lowers Price Target to $100

Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 80 extraordinary options activities for Apple. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 43% bearish. Among these notable options, 18 are puts, totaling $2,635,916, and 62 are calls, amounting to $3,937,782.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $285.0 for Apple during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apple's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale trades within a strike price range from $100.0 to $285.0 in the last 30 days. 
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693833_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$227.50</td>
<td>$1.8M</td>
<td>2.0K</td>
<td>6.7K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$135.5</td>
<td>$134.7</td>
<td>$135.13</td>
<td>$100.00</td>
<td>$270.2K</td>
<td>1.1K</td>
<td>30</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$12.9</td>
<td>$13.1</td>
<td>$260.00</td>
<td>$262.0K</td>
<td>14.4K</td>
<td>221</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.73</td>
<td>$275.00</td>
<td>$240.9K</td>
<td>6.6K</td>
<td>281</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$134.95</td>
<td>$134.25</td>
<td>$134.67</td>
<td>$100.00</td>
<td>$188.5K</td>
<td>1.1K</td>
<td>74</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
After a thorough review of the options trading surrounding Apple, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Apple</h3>
<ul>
<li>Trading volume stands at 24,595,000, with AAPL's price up by 1.67%, positioned at $231.82.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>What The Experts Say On Apple</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $264.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Apple, targeting a price of $275. 
&#x2A; An analyst from Loop Capital has revised its rating downward to Hold, adjusting the price target to $230. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Apple with a target price of $294. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Apple, targeting a price of $265. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Apple's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 105 uncommon options trades for Taiwan Semiconductor.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 40%, bearish.
Out of all of the special options we uncovered, 43 are puts, for a total amount of $4,591,158, and 62 are calls, for a total amount of $8,659,150.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $330.0 for Taiwan Semiconductor, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Taiwan Semiconductor's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Taiwan Semiconductor's significant trades, within a strike price range of $90.0 to $330.0, over the past month.
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693828_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$9.95</td>
<td>$9.85</td>
<td>$9.95</td>
<td>$220.00</td>
<td>$1.2M</td>
<td>10.5K</td>
<td>1.3K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$9.9</td>
<td>$9.85</td>
<td>$9.86</td>
<td>$210.00</td>
<td>$344.7K</td>
<td>10.2K</td>
<td>676</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$47.45</td>
<td>$46.6</td>
<td>$47.0</td>
<td>$180.00</td>
<td>$282.0K</td>
<td>2.8K</td>
<td>106</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$36.4</td>
<td>$35.2</td>
<td>$36.15</td>
<td>$200.00</td>
<td>$180.6K</td>
<td>133</td>
<td>50</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.81</td>
<td>$240.00</td>
<td>$146.1K</td>
<td>2.9K</td>
<td>346</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the US in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
Following our analysis of the options activities associated with Taiwan Semiconductor, we pivot to a closer look at the company's own performance.
<h3>Taiwan Semiconductor's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,951,459, with TSM's price up by 2.15%, positioned at $204.1.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>Expert Opinions on Taiwan Semiconductor</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $240.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $225. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Taiwan Semiconductor, which currently sits at a price target of $255. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Taiwan Semiconductor, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Taiwan Semiconductor Unusual Options Activity For February 04

Whales with a lot of money to spend have taken a noticeably bearish stance on Upstart Hldgs.
Looking at options history for Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $700,805 and 10, calls, for a total amount of $611,608.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $52.5 to $100.0 for Upstart Hldgs during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Upstart Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Upstart Hldgs's substantial trades, within a strike price spectrum from $52.5 to $100.0 over the preceding 30 days.
<h3>Upstart Hldgs Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738693823_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.6</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$70.00</td>
<td>$144.4K</td>
<td align="right">851</td>
<td align="right">578</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$23.8</td>
<td>$23.2</td>
<td>$23.8</td>
<td>$67.50</td>
<td>$142.8K</td>
<td align="right">42</td>
<td align="right">60</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$6.05</td>
<td>$5.65</td>
<td>$5.85</td>
<td>$60.00</td>
<td>$140.4K</td>
<td align="right">11</td>
<td align="right">241</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$52.50</td>
<td>$103.9K</td>
<td align="right">279</td>
<td align="right">232</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$17.35</td>
<td>$17.3</td>
<td>$17.35</td>
<td>$79.00</td>
<td>$69.4K</td>
<td align="right">50</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Upstart Hldgs</h3>
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
In light of the recent options history for Upstart Hldgs, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Upstart Hldgs</h3>
<ul>
<li>With a trading volume of 1,485,413, the price of UPST is up by 1.3%, reaching $63.99.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Upstart Hldgs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

UPST

Market Whales and Their Recent Bets on UPST Options

Retirement is the time when work takes a backseat, and the focus shifts to enjoying life's quieter moments. You might expect net worth to decline once <a href="https://www.benzinga.com/personal-finance/24/10/41127976/are-you-a-rich-retiree-heres-the-net-worth-and-income-you-need-to-be-in-the-top-10">retirees start dipping into their savings</a>, but here's the twist: for many retirees, net worth doesn't just hold steady—it grows.
Recent data shows a surprising trend. The average retiree's net worth not only remains solid but actually sees a noticeable increase, especially in the early years of retirement.
Retiree Net Worth by the Numbers
For retirees aged 65 to 74, the average net worth is an impressive $1,794,600, while the median net worth sits at $409,900. The gap between these figures highlights the role of wealth inequality—while some retirees have considerable assets, others don't have nearly as much, pulling the median lower.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
As retirees age, the numbers remain striking. For those 75 and older, the average net worth is around $1,624,100, with a median net worth of $335,600. Even as seniors begin drawing from their savings, many still maintain a solid financial cushion.
Why Does Net Worth Grow After Retirement?
The idea of net worth growing during retirement might seem counterintuitive, but several factors contribute to this trend:
<ul>
<li>Reduced Expenses: <a href="https://www.benzinga.com/personal-finance/24/07/39866450/the-average-retiree-spends-over-52-000-a-year-and-75-of-that-goes-to-just-five-expenses-how-does">Retirees often spend less</a>, especially on work-related costs like commuting, professional attire, or meals on the go. This reduced spending allows savings and investments to stretch further.</li>
<li>Reliable Income Sources: <a href="https://www.benzinga.com/personal-finance/25/01/42850946/planning-your-retirement-new-changes-to-social-security-in-2025-could-affect-you">Social Security and pensions</a> provide steady income, while many retirees benefit from appreciating assets, such as home values and investments.</li>
<li>Healthcare Costs Stabilize: Medicare kicks in at 65, easing the financial burden of healthcare for many retirees, though individual costs may still vary.</li>
</ul>
These factors combined help retirees grow or maintain their wealth, even as they transition into their post-work years.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The Wealth Gap: Gender Differences in Retirement
While average figures paint a rosy picture, not everyone's retirement story looks the same. A glaring wealth gap persists, particularly between men and women. Here are some statistics from the U.S. Department of Labor:
<ul>
<li>Women aged 50 and older have about $0.77 in wealth for every dollar held by men.</li>
<li>The median retirement savings for women is $43,000, less than half of men's $91,000.</li>
<li>Only 22% of women have saved $100,000 or more for retirement, compared with 30% of men.</li>
<li>Meanwhile, 25% of women report saving less than $10,000—or nothing at all—compared with 16% of men.</li>
</ul>
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Key Takeaways for Retirees
The disparity in net worth shows the importance of financial planning, especially as retirement nears. For retirees who plan carefully, there's a strong chance of maintaining or even growing their net worth, thanks to a mix of lower expenses, stable income, and strategic investing.
At the same time, gaps in wealth and savings point to the need for better retirement strategies, particularly for women, who tend to face unique financial challenges. Addressing these gaps could help ensure a more secure and equitable retirement for everyone.
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Planning for a Secure and Rewarding Retirement
Retirement isn't just the end of a career—it's a chance to watch your hard work and financial discipline come to life. Whether you're just starting to save or you're already looking ahead to life after work, these trends show that a stable, even growing, net worth is possible with the right approach.
<a href="https://www.benzinga.com/money/are-you-rich">Consulting a financial advisor</a> can make a big difference, helping you tailor a plan that fits your goals and ensures you're making the most of your resources.
Retirement doesn't have to mean cutting back—it can mean thriving. With the right guidance and effort, those golden years can shine brighter than you'd ever imagined.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

Can You Guess The Average Retiree's Net Worth? Surprisingly, It Tends To Skyrocket During Retirement

BREA, MSAI and APM among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Creative Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) just reported results for the first quarter of 2024.<ul><li>Creative Medical Tech reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -$1.15.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/celz-stock-earnings-creative-medical-tech-for-q1-of-2024/">CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Creative Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) just reported results for the second quarter of 2024.<ul><li>Creative Medical Tech reported earnings per share of -$1.11. This was below the analyst estimate for EPS of -84 cents.</li><li>The company reported revenue of $8,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/celz-stock-earnings-creative-medical-tech-for-q2-of-2024/">CELZ Stock Earnings: Creative Medical Tech Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CELZ Stock Earnings: Creative Medical Tech Misses EPS for Q2 2024

Creative Medical Technology files for $50M mixed securities shelf

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.

Are Pharma Stocks Harmful To Your Financial Health ?

Creative Medical Technology (CELZ) Holdings has entered into definitive securities purchase agreements with certain institutional investors for the...

Creative Medical to sell 418,552 shares at $4.42 in registered direct offering

16:08 EST Creative Medical Technology (CELZ) files to sell 837,104 shares of common for holders Published first on TheFly – the ultimate source for...

Creative Medical Technology files to sell 837,104 shares of common for holders

Creative Medical Technology files to sell 0.83M shares of common stocks by selling shareholders

Creative Medical Technology (CELZ) announces the successful completion of an independent interim safety review by the Data Safety Monitoring Board,...

Creative Medical advances FDA cleared ADAPT trial with independent review

Creative Medical Technology (CELZ) announced initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Compan...

Creative Medical reports data from first cohort in Phase 1/2 CELZ-201-DDT trial

APVO

AVGR

BIAF

BREA

CELZ

GROM

IFBD

IMRN

MAXN

MBIO

MSAI

NTRB

Biotech Finds Mid-Week Success Following FDA Announcement

Press Releases

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Comments

Creative Medical Tech

Creative Medical Tech (CELZ) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL